Press Release

Triple-Negative Breast Cancer Market Research Report 2018-2030: Analysis of Domain, Therapies, Epidemiology and Key Companies in 7MM by DelveInsight

TNBC Market

DelveInsight’s Triple Negative Breast Cancer Market Insights Report offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities and treatment options. 

The report also offers comprehensive insights into Triple Negative Breast Cancer market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing Triple Negative Breast Cancer clinical trials, collaboration in the space, and key pharmaceutical companies actively pushing the growth of Triple-Negative Breast Cancer market size forward in the 7MM [US, EU5(Germany, France, the United Kingdom, Spain, and Italy) and Japan].

Some of the key highlights from the Triple Negative Breast Cancer Market Insights: 

  • TNBC Market Size in the 7MM was found to be USD 438 Million in 2017.
  • The United States accounted for the largest market size of TNBC, in comparison to the other 7MM countries.
  • Total Diagnosed Incident cases of TNBC in the 7MM countries was 99,380 in 2017.
  • Amongst all the 7MM countries, the EU-5 countries (combined) accounted for the highest number of incident cases, followed by the US in the year 2017.
  • Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC and accounted for 12,516 cases, followed by France and Italy in the year 2017.
  • Upcoming therapies such as Ipatasertib (Hoffmann-La Roche), Pembrolizumab (Imprime PGG; HiberCell), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn) and CFI-400945 (Treadwell Therapeutics) have the potential to create a significant positive shift in the TNBC market size during the study period.

Triple-Negative Breast Cancer Overview:

Triple-Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

Triple-Negative Breast Cancer Symptoms:

Symptoms include Breast pain or redness, A lump or mass in the breast and a nipple that turns inward or has a discharge. 

For more insights into Disease, causes and treatment, reach out to Triple-Negative Breast Cancer Treatment Landscape.

Triple-Negative Breast Cancer Epidemiology Segmentation 

The Triple Negative Breast Cancer Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Triple-Negative Breast Cancer Prevalence 
  • Severity Specific Triple Negative Breast Cancer Prevalence 
  • Diagnosed and Treatable Cases of Triple-Negative Breast Cancer

Visit for more @Triple Negative Breast Cancer Epidemiological Insights.

Triple-Negative Breast Cancer Pipeline Therapies and Key Companies 

  • Lynparza: AstraZeneca
  • Tercentriq (Atezolizumab): Hoffmann-La Roche
  • Sacituzumab Govitecan-hziy: Immunomedics
  • Keytruda: Merck
  • Imprime PGG : HiberCell
  • Ipatasertib: Hoffmann-La Roche
  • IPI-549: Infinity Pharmaceuticals
  • Leronlimab (PRO 140): CytoDyn
  • And Many Others

For more information, visit Triple Negative Breast Cancer Market Analysis, Patient Pool and Emerging Therapies.

Scope of the Report

  • 11 Year Forecast
  • 7MM Coverage 
  • Descriptive overview of Triple-Negative Breast Cancer, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight into Triple Negative Breast Cancer epidemiology and treatment in the 7MM
  • Current and emerging therapies for Triple-Negative Breast Cancer
  • Triple-Negative Breast Cancer market drivers and barriers 

Get in touch with our Business executive @ Triple Negative Breast Cancer Market Landscape Analysis.

Table of Contents 

1.

Key Insights

2.

Report Introduction

3.

Competitive Intelligence Analysis for Triple Negative Breast Cancer

4.

Triple Negative Breast Cancer Market Overview at a Glance

5.

Executive Summary of Triple Negative Breast Cancer

6.

Triple Negative Breast Cancer Epidemiology and Market Methodology

7.

Triple Negative Breast Cancer Epidemiology and Patient Population

8.

Triple Negative Breast Cancer Patient Journey

9.

Treatment Algorithm, Current Treatment, and Medical Practices

10.

Key Endpoints in Triple Negative Breast Cancer Clinical Trials

11.

Triple Negative Breast Cancer Marketed Therapies 

12.

Triple Negative Breast Cancer Emerging Therapies

13.

Triple Negative Breast Cancer: 7 Major Market Analysis

14.

Attribute analysis

15.

Access and Reimbursement Overview of Triple Negative Breast Cancer

16.

KOL Reviews

17.

Case Reports

18.

Triple Negative Breast Cancer Market Drivers

19.

Triple Negative Breast Cancer Market Barriers

20.

SWOT Analysis

21.

Disclaimer

21.

DelveInsight Capabilities

22.

About DelveInsight

Learn more about the report offerings @ Triple Negative Breast Cancer Market Outlook

Related Reports:

Her2 Negative Breast Cancer Market

 DelveInsight’s ‘Her2 Negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030′ report will provide Her2 Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Eisai, G1 Therapeutics, Genetech/La Roche, Sanofi, AstraZeneca and several others. 

Her2 Positive Breast Cancer Market

DelveInsight’s “Her2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report will provide Her2 Positive Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Roche, Kadcyla, Genentech, Novartis, Puma Biotechnology, Seattle Genetics, MacroGenics, Prestige Biopharma, EirGenix, Roche, Genentech, Pfizer, Merck, Eli Lilly, Horizon Pharma and several others.

Her2 Positive Early Breast Cancer Market

DelveInsight’s ‘Her2 Positive Early Breast Cancer Market Insights, Epidemiology and Market Forecast – 2030’ report will provide Her2 Positive Early Breast Cancer Market, Epidemiological and Therapeutics market domain.

Her2 Negative Metastatic Breast Cancer Market

DelveInsight’s “Her2 Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report. 

Metastatic Triple-Negative Breast Cancer Market

DelveInsight’s “Metastatic Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report will provide Metastatic Triple-Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Immunomedics, Merck, Roche, Pfizer, Astellas, Hoffman La Roche, Tesaro, AstraZeneca, Cytodyn and several others.

Brain Metastasis From Breast Cancer Pipeline

DelveInsight’s “Brain Metastasis from Breast Cancer Pipeline Insights, 2021,” report provides comprehensive insights about companies and pipeline drugs, including Angiochem, Northwest Biotherapeutics, Merck, Novartis Pharmaceuticals, Abbott, Ipsen, Puma Biotechnology, Cortese Biosciences, Onconova Therapeutics and several others. 

Related Posts:

Key Facts To Know About Triple-Negative Breast Cancer

7 Most Common Myths About Breast Cancer Demystified

Breast Cancer: Understand your breasts, recognize the symptoms

How HR+/ HER2-Breast Cancer emerging drugs will transform the market?

Global HR+/ HER2- Breast Cancer Market Scenario

Triple Negative Breast Cancer Responds to TINAGL Therapy

About DelveInsight 

DelveInsight is a leading Market Research, and Business Consultant focused purely on life sciences. It assists pharma companies by providing them with end-to-end solutions to boost their performance.

Get access to all the Pharma and healthcare market research reports through our market research subscription-based platform PharmDelve.

Connect With Us at:

LinkedIn | Facebook | Twitter

Get Free Sample Copy of Report at:

 https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Tags: , , , ,

Contact Information:

 Ankit Nigam
 [email protected]
 +91-9650213330